Immunization is among the most impactful and cost-effective health investments a nation can make. However, with the introduction of new vaccines, the cost to vaccinate a child continues to rise. Many low- and middle-income countries that currently receive financial support for their immunization programs will no longer be eligible by 2020 due to their growing economies, and must therefore transition away from external financing and toward country ownership.
Resources & Publications
In light of rising outbreaks of measles and other vaccine-preventable diseases in Europe, the Sabin Vaccine Institute in 2018 conducted a review of immunization legislation in the region.
Streptococcus pneumoniae remains an important cause of pneumonia and invasive bacterial disease, primarily meningitis and sepsis. The greatest burden of disease occurs in low-and middle-income countries, and the risk of serious pneumococcal disease peaks at the extreme ages of life. Young children are at highest risk, but older adults and people with immuno-compromising conditions also suffer high rates of pneumococcal disease.
The Sabin Vaccine Institute, in collaboration with international partners and the Government of Georgia, organized a Workshop on Immunization Legislation that gathered the three European countries of Sabin’s Sustainable Immunization Financing Program (SIF), Armenia, Georgia and Moldova, in Tbilisi, Georgia, on 1-2 March 2017.
Институт вакцин им. Сабина в сотрудничестве с международными партнёрами и правительством Грузии организовал Семинар по законодательству об иммунопрофилактике, в котором приняли участие три европейские страны-участницы Программы устойчивого финансирования иммунизации Сабина-Армения, Грузия и Молдова. Семинар состоялся в Тбилиси 1-2 марта 2017 года.